Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E, Hernandez KM, Kim CR, Harkless RV, Oh A, Bowie KR, West-Szymanski DC, Betancourt-Ponce MA, Green BD, Lastra RR, Fleming GF, Chandarlapaty S, Conzen SD. Tonsing-Carter E, et al. Among authors: fleming gf. Breast Cancer Res. 2019 Jul 24;21(1):82. doi: 10.1186/s13058-019-1164-6. Breast Cancer Res. 2019. PMID: 31340854 Free PMC article.
Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.
Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD. Melhem A, et al. Among authors: fleming gf. Clin Cancer Res. 2009 May 1;15(9):3196-204. doi: 10.1158/1078-0432.CCR-08-2131. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383827 Free PMC article. Clinical Trial.
Phase II trial of temsirolimus in patients with metastatic breast cancer.
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Fleming GF, et al. Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13. Breast Cancer Res Treat. 2012. PMID: 22245973 Free PMC article. Clinical Trial.
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group. Regan MM, et al. Among authors: fleming gf. Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22. Breast Cancer Res Treat. 2015. PMID: 26493064 Free PMC article.
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.
Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD. Nanda R, et al. Among authors: fleming gf. Springerplus. 2016 Jun 30;5(1):947. doi: 10.1186/s40064-016-2457-1. eCollection 2016. Springerplus. 2016. PMID: 27386391 Free PMC article.
233 results